Insights into the neurobiology of functional movement disorders

At a joint MDS-European Section and EAN 2019 workshop session focusing on “Functional movement disorders”, the areas of clinical diagnosis, biological background and management were explored. Neurobiological insights show that functional disorders are not mysterious or unexplained phenomena. Expanding our understanding of the neurobiology of functional movement disorders may lead to improved treatment in future.

Neurobiology of FMD

The fact that functional movement disorders (FMD) are not strange, mysterious or particularly unexplained phenomena was emphasized during a workshop presentation at the EAN 2019 Congress.

Functional disorders are not strange, mysterious or particularly unexplained phenomena

An FMD is a condition where a person experiences abnormal function in a system that is capable of normal function when attention is diverted from the abnormal movements or from peripheral signals.1Understanding the neurobiological mechanisms of FMD allows us to explain “how things have gone wrong”. However, in order to understand how functional disorders occur, we first need to appreciate the process of normal functioning.

Understanding the neurobiological mechanisms of FMD allows us to explain “how things have gone wrong”.

 

The brain as a processor

The brain is an organ that mediates the relationship between “us”, our bodies, and the world. There are two types of data sources that guide action and perception in a dynamic fashion:

  • Sensory data (feedback) – “bottom up”
  • Predictions about (future) sensory data (feed-forward) – “top down”.

Our experience of our bodies and the world is a fluid, changeable phenomenon modulated by predictive systems that play a role in “ownership” over our bodies and movement. Functional disorders are a problem at the interface between you and the body itself at the level of predictions and attention to the body. In FMD, movement is not identified correctly as coming from the self, and so is experienced as “out of control”.2,3

In FMD, movement is not identified correctly as coming from the self, and so is experienced as “out of control”.

 

Trigger events

FMD commonly occur after a physical precipitating factor or event, e.g. after injury, infection, neurological disorder, pain, adverse drug reaction, or surgery.4-6 The new salient information about the body acts as a trigger of malfunction of the predictive systems.
Stressful life events and maltreatment may be considered as risk factors for FMD rather than causes.7 Neurobiological interest focuses on how these risk factors generate vulnerability in relevant systems.

 

Epidemiology of FMD

New cases of FMD arise in 4-12 people per 100,000 annually, and FMD have a prevalence of 50 per 100,000 in the community among whom 5% of cases are referred to a Neurology service.8 The age of onset of FMD is 35-50 years, and women are more likely to be affected (60-85% of cases).
FMD typically manifest as tremor of the limbs, dystonia, myoclonus, gait disorders and Parkinsonism. FMD are common, persistent and associated with disability, and may be diagnosed by a combination of clinical history, examination and electrophysiology.

FMD are common, persistent and associated with disability

 

Management of functional disorders

The management of functional disorders is multimodal and may include physiotherapy, neurology, psychiatry, and chronic pain services.9 Currently, obstacles to effective treatment include limited evidence from randomized controlled trials, an absence of guidelines, and lack of determinants of outcome for different approaches. Further elucidation of the neurobiology of functional disorders may lead to new treatments.

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References

1 Edwards MJ et al. Neurobiology of functional (psychogenic) movement disorders. Curr Opin Neurol. 2013;26:442-7.

2 Brown H et al. Active inference, sensory attenuation and illusions. Cogn Process. 2013;14:411-27.

3 Parees I et al. Loss of sensory attenuation in patients with functional (psychogenic) movement disorders. Brain. 2014;137 (Pt 11):2916-21.

4 Parees I et al. Physical precipitating factors in functional movement disorders. J Neurol Sci. 2014;338:174-77.

5 Stone J et al. Functional weakness: clues to mechanism from the nature of onset. J Neurol Neurosurg Psychiatry. 2012;83:67-9.

6 Edwards MJ et al. A Bayesian account of 'hysteria'. Brain. 2012;135 (Pt 11):3495-512.

7 Ludwig L et al. Stressful life events and maltreatment in conversion (functional neurological) disorder: systematic review and meta-analysis of case-control studies. Lancet Psychiatry. 2018;5:307-20.

8 Stone J et al. Who is referred to neurology clinics?-the diagnoses made in 3781 new patients. Clin Neurol Neurosurg. 2010;112:747-51.

9 Gelauff JM et al. Treatment of functional movement disorders. Curr Treat Options Neurol. 2014;16:286.

Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country